SG1827 is a novel recombinant human CD80 variant-Fc fusion protein that co-stimulates T cell activation. It has demonstrated phenomenal anti tumor activities in both monotherapy and combo treatment with ICIs such as PD-1 inhibitor. SG1827 has received IND clearance from NMPA and a Ph I clinical trial for the treatment of late stage solid tumor is ongoing in China.
Copyright Rm. 301, F3, Building C, Block 2, No. 688, Bin'an Road, Changhe Zhejiang ICP Filing No. 18039044
